Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 4/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.74 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.74 |
| ▸ | ESR1 | P03372 | 4/20 | 0.74 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.74 |
| ▸ | ABL1 | P00519 | 2/20 | 0.74 |
| ▸ | TTR | P02766 | 2/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.74 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.74 |
| ▸ | BCR | P11274 | 2/20 | 0.74 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.74 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.74 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.74 |
| ▸ | TUBB | P07437 | 2/20 | 0.74 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.74 |
| ▸ | AHR | P35869 | 2/20 | 0.74 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.74 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.74 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6803777 | 1.00 | NQO2 (1.00) | NQO2CYP1A1CYP1B1ESR1NFE2L2 | |
| SCHEMBL2131725 | 1.00 | NQO2 (1.00) | NQO2CYP1A1CYP1B1ESR1NFE2L2 | |
| SCHEMBL18002818 | 0.88 | NQO2 (0.77) | NQO2CYP1A1CYP1B1ESR1NFE2L2 | |
| SCHEMBL22589828 | 0.88 | NQO2 (0.77) | NQO2CYP1A1CYP1B1ESR1NFE2L2 | |
| SCHEMBL22589830 | 0.88 | NQO2 (0.77) | NQO2CYP1A1CYP1B1ESR1NFE2L2 | |
| SCHEMBL22589832 | 0.88 | NQO2 (0.77) | NQO2CYP1A1CYP1B1ESR1NFE2L2 | |
| SCHEMBL22589833 | 0.88 | NQO2 (0.77) | NQO2CYP1A1CYP1B1ESR1NFE2L2 | |
| SCHEMBL5495425 | 0.85 | NFE2L2 (1.00) | NQO2CYP1A1CYP1B1ESR1NFE2L2 | |
| SCHEMBL5495422 | 0.85 | NFE2L2 (1.00) | NQO2CYP1A1CYP1B1ESR1NFE2L2 | |
| Trismethoxyresveratrol SCHEMBL918739 | 0.85 | CYP1A1 (1.00) | NQO2CYP1A1CYP1B1ESR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585713-A1 | NEW STILBENE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR LIGAND ANTAGONISTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2005-10-19 | — | — | EP | disclosed |
| US-20040147788-A1 | Stilbene derivatives and their use as aryl hydrocarbon receptor antagonistic ligands | INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (I.N.S.E.R.M.) (FR) | 2004-07-29 | — | — | US | disclosed |
| WO-2004041758-A1 | NEW STILBENE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR LIGAND ANTAGONISTICS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (I.N.S.E.R.M.) (FR) | 2004-05-21 | — | — | WO | disclosed |
| EP-1418164-A1 | New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2004-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147788-A1 | Stilbene derivatives and their use as aryl hydrocarbon receptor antagonistic ligands | AHR, HCAR3, HCAR1 | NQO2 1587/4885CYP1A1 72/4885CYP1B1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.